CPT Code Overview

CPT 81456 is a genomic sequencing analysis panel that detects RNA alterations across 51 or more genes, commonly performed for tumor or bone marrow specimens. This code represents a comprehensive RNA-based multigene panel used to identify clinically relevant genomic alterations that can inform diagnosis, prognosis, or targeted therapy selection.

Service type: Genomic Sequencing Procedures and Other Molecular Multianalyte Assays

Typical site of service: Laboratory (e.g., independent or hospital reference lab)

Clinical Context

A patient with a suspected or confirmed solid organ malignancy (examples include primary lung, liver, colorectal, breast, or metastatic disease) undergoes tissue biopsy or resection. The specimen is sent to a reference molecular pathology laboratory for comprehensive RNA-based genomic sequencing to identify gene fusions, splice variants, or other RNA alterations across a broad panel of genes. The laboratory performs nucleic acid extraction, library preparation, sequencing, and bioinformatic analysis, and a pathologist or molecular geneticist interprets and issues a report to the treating oncology team for potential therapeutic targeting, clinical trial eligibility, or prognostic information.

Coding Specifications

• Modifier 26: Professional component — used when billing for the interpretation and reporting component performed by a qualified professional (e.g., pathologist or molecular geneticist).

• Modifier TC: Technical component — used when billing for the laboratory technical services (e.g., specimen processing, sequencing, instrumentation, and technician labor) without the professional interpretation.

Associated Provider Taxonomies

• Pathology - Clinical Pathology/Laboratory Medicine (207ZP0102X): laboratory medicine specialists involved in test oversight and result validation.

• Pathology - Molecular Genetic Pathology (207ZP0105X): specialists who interpret molecular sequencing data and prepare the clinical report.

• Anatomic Pathology & Clinical Pathology (207L00000X): combined anatomic and clinical pathology practitioners who may oversee both specimen handling and result interpretation.

Related Diagnoses

• C00.0–C79.x (solid organ neoplasms): Solid organ neoplasms supporting medical necessity, as listed in CMS Billing & Coding Article A56867

• Clinical relevance: These diagnosis codes represent primary or metastatic solid organ cancers (for example, malignancies of lung, liver, colon, breast, kidney, or other solid organs). RNA-based genomic sequencing panels such as 81456 are used to detect actionable RNA alterations (such as gene fusions or splice variants) that can inform targeted therapy selection, prognostic assessment, or clinical trial eligibility in patients with these diagnoses.

Related CPT Codes

• 81455: Represents a combined DNA and RNA panel covering 51 or more genes; may be ordered when both DNA and RNA alterations are clinically relevant. It can be used together with 81456 if separate billing is appropriate for distinct assays, or as an alternative when a combined DNA/RNA assay is performed.

• 81449 and 81451: Represent targeted RNA panel methods using separate techniques; these may be used as alternative, smaller or method-specific RNA assays in workflows where a focused RNA test is sufficient instead of the broader 81456 panel. These codes may be used in place of 81456 when the scope or method of testing differs.

Across the national benchmarks, BUCA (the aggregated commercial benchmark) posts a mean rate marginally above the mean for Blue Cross Blue Shield and Aetna, with BUCA at $2,394.48 versus an implied Medicare value not provided in the input. This positions BUCA as slightly higher than several large commercial payers on average and below Cigna, which has the highest mean at $2,730.34.

Rate dispersion (P75 minus P25) is widest for Cigna at $2,024.00 (3,504.00 - 1,480.00) and also notably wide for BCBS at $1,361.00. Dispersion is tightest for Aetna at $865.00 and for BUCA at $1,116.67. The table and chart below present the full breakdown of mean rates and percentiles for each payer.